| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.31.10.975 |
| P698 | PubMed publication ID | 21950643 |
| P2093 | author name string | Jennifer A Campbell | |
| Kathleen A Packard | |||
| Estella M Davis | |||
| Jon T Knezevich | |||
| P2860 | cites work | Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists | Q24647947 |
| Bivalirudin for patients with acute coronary syndromes | Q28210982 | ||
| An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators | Q28254763 | ||
| Dabigatran versus warfarin in patients with atrial fibrillation | Q28256895 | ||
| New oral anticoagulants in atrial fibrillation | Q28261825 | ||
| 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines | Q28305368 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial | Q34102430 | ||
| Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome | Q34129340 | ||
| Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Q34134664 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after hip replacement | Q34156023 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor | Q34381344 | ||
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial | Q34607209 | ||
| Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers | Q34615829 | ||
| Rivaroxaban: a new oral factor Xa inhibitor | Q34616521 | ||
| Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study | Q34617523 | ||
| Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers | Q34620374 | ||
| Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial | Q34624280 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty | Q34789112 | ||
| Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty | Q34789118 | ||
| Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial | Q34789474 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| Advancement in antithrombotics for stroke prevention in atrial fibrillation | Q37143256 | ||
| Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme | Q37383508 | ||
| Newer anticoagulants in 2009. | Q37617159 | ||
| Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review | Q37661890 | ||
| Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). | Q37810274 | ||
| Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments | Q37818783 | ||
| New oral anticoagulants | Q37843749 | ||
| Drug and dietary interactions of warfarin and novel oral anticoagulants: an update | Q37848142 | ||
| Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure | Q40359866 | ||
| The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects | Q41121441 | ||
| Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards | Q42791455 | ||
| Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial | Q42830264 | ||
| Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation | Q42839725 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats | Q43069087 | ||
| Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale | Q43138658 | ||
| Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). | Q43188583 | ||
| In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
| Apixaban: an emerging oral factor Xa inhibitor | Q43240015 | ||
| A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting | Q43267101 | ||
| The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation | Q43279486 | ||
| Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial | Q43283673 | ||
| Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial | Q44672192 | ||
| Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale | Q45137335 | ||
| Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Q45962608 | ||
| Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. | Q45995789 | ||
| Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran | Q46045990 | ||
| Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study | Q46550059 | ||
| Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). | Q46939643 | ||
| Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation | Q49811601 | ||
| New oral anticoagulants in development. | Q50276490 | ||
| Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada | Q53064705 | ||
| The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. | Q53229008 | ||
| Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. | Q53244860 | ||
| Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. | Q54135542 | ||
| Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. | Q55053661 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulant | Q215118 |
| acute coronary syndrome | Q266018 | ||
| atrial fibrillation | Q815819 | ||
| anticoagulation | Q63279445 | ||
| P304 | page(s) | 975-1016 | |
| P577 | publication date | 2011-10-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome | |
| P478 | volume | 31 |
| Q54561846 | Acute ischemic stroke following cardioversion in a patient receiving dabigatran. |
| Q36108384 | An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation |
| Q37590158 | Atrial fibrillation: mechanisms, therapeutics, and future directions |
| Q34993935 | Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis |
| Q26996325 | High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis |
| Q34670994 | Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs |
| Q38038905 | New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function |
| Q38838530 | Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. |
| Q38124014 | Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly |
| Q43594298 | Oral factor Xa inhibitors for the long-term management of ACS. |
| Q38163036 | Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation |
| Q38033194 | Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis |
| Q38888217 | Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants |
Search more.